Skip to Content

'
Vassiliki Papadimitrakopoulou, M.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Thoracic/Head and Neck Medical Oncology, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1988 University of Patras School of Medicine, Patras, Greece, MD, Medicine

Postgraduate Training

7/1994-6/1997 Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
7/1991-6/1994 Clinical Residency, Internal Medicine, Columbia Presbyterian Medical Center, New York City
1/1990-6/1991 Clinical Residency, Institut Gustave Roussy, Unite La Grange, Savigny Le Temple, France
10/1988-11/1989 Clinical Internship, Metaxas Cancer Hospital, Piraeus, Greece

Board Certifications

1/1997 Internal Medicine, Medical Oncology
1/1994 Internal Medicine

Experience/Service

Academic Appointments

Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 10/2003-8/2009
Assistant Professor, Department of Thoracic/Head & Neck Medical Oncology, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 10/1998-8/2003
Instructor, Department of Thoracic/Head & Neck Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 7/1997-8/1998

Selected Publications

Peer-Reviewed Original Research Articles

1. Kies MS, Holsinger FC, Lee JJ, William WN, Glisson BS, Lin HY, Lewin JS, Ginsberg LE, Gillaspy KA, Massarelli E, Byers L, Lippman SM, Hong WK, El-Naggar AK, Garden AS, Papadimitrakopoulou V. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck (SCCHN): Results from a Phase II prospective trial. J Clin Oncol 28(1):8-14, 1/2010. e-Pub 11/2009. PMCID: PMC2799235.
2. Tsao AS, Liu D, Martin J, Tang XM, Lee JJ, El-Naggar AK, Wistuba I, Culotta KS, Mao L, Gillenwater A, Sagesaka YM, Hong WK, Papadimitrakopoulou V. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila Pa) 2(11):931-41, 11/2009. PMID: 19892663.
3. Saintigny P, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim ES, Hong WK, Lippman SM, Mao L. DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer inpatients with leukoplakia. Clin Cancer Res 15(19):6284-91, 10/1/2009. e-Pub 9/22/2009. PMCID: PMC2756317.
4. Soria JC, Shepherd FA, Douillard JY, Wolf J, Giaccone G, Crino L, Cappuzzo F, Sharma S, Gross SH, Dimitrijevic S, Di Scala L, Gardner H, Nogova L, Papadimitrakopoulou V. Efficacy of Everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol 20(10):1674-91, 10/2009. e-Pub 6/2009. PMID: 19549709.
5. Saba NF, Choi M, Muller S, Shin HJ, Tighiouart M, Papadimitrakopoulou VA, El-Naggar AK, Khuri FR, Chen ZG, Shin DM. Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma. Cancer Prev Res (Phila Pa) 2(9):823-9, 9/2009. e-Pub 9/8/2009. PMCID: PMC2910364.
6. Papadimitrakopoulou VA, Lee JJ, William WN, Martin JW, Thomas M, Kim ES, Khuri FR, Shin DM, Feng L, Hong WK, Lippman SM. Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol 27(4):599-604, 2/1/2009. e-Pub 12/15/2008. PMCID: PMC2645856.
7. Papadimitrakopoulou V, Izzo JG, Liu DD, Myers J, Ceron TL, Lewin J, William WN, Atwell A, Lee JJ, Gillenwater A, El-Naggar A, Wu X, Lippman SM, Hittelman WN, Hong WK. Cyclin D1 and cancer development in laryngeal premalignancy patients. Cancer Prev Res (Phila Pa) 2(1):14-21, 1/2009. PMID: 19139013.
8. William WN, Lee JJ, Lippman SM, Martin JW, Chakravarti N, Tran HT, Sabichi AL, Kim ES, Feng L, Lotan R, Papadimitrakopoulou VA. High dose Fenretinide in oral leukoplakia. Cancer Prev Res (Phila Pa) 2(1):22-6, 1/2009. PMID: 19139014.
9. Papadimitrakopoulou VA, William WN, Dannenberg AJ, Lippman SM, Lee JJ, Ondrey FG, Peterson DE, Feng L, Atwell A, El-Naggar AK, Nathan CO, Helman JI, Du B, Yueh B, Boyle JO. Pilot randomized Phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res 14(7):2095-101, 4/1/2008. PMID: 18381950.
10. Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim E, Hong WK, Lippman SM, Mao L. Podoplanin: A novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 26:354-60, 2008.
11. Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res 12(14 Pt 2):441S-445S, 7/15/2006. PMID: 16857825.
12. Papadimitrakopoulou VA, Brown EN, Liu DD, El-Naggar AK, Jack Lee J, Hong WK, Lee HY. The Prognostic Role of Loss of Insulin-like Growth Factor-binding Protein-3 Expression in Head and Neck Carcinogenesis. Cancer Lett 239(1):136-43, 7/2006. e-Pub 9/2005. PMID: 16181731.
13. Lippman SM. Lee JJ. Martin JW. El-Naggar AK. Xu X. Shin DM. Thomas M. Mao L. Fritsche HA Jr. Zhou X. Papadimitrakopoulou V. Khuri FR. Tran H. Clayman GL. Hittelman WN. Hong WK. Lotan R. Fenretinide activity in retinoid-resistant oral leukoplakia. [Clinical Trial, Phase II. Research Support, N.I.H., Extramural]. Clin Cancer Res 12:3109-14, 2006.
14. Gillenwater A. Papadimitrakopoulou V. Richards-Kortum R. Oral premalignancy: new methods of detection and treatment. Curr Oncol Reports:146-54, 2006.
15. Tsao AS, Garden AS, Kies MS, Morrison W, Feng L, Lee JJ, Khuri F, Zinner R, Myers J, Papadimitrakopoulou V, Lewin J, Clayman GL, Ang KK, Glisson BS. Phase I/II Study of Docetaxel, Cisplatin, and Concomitant Boost Radiation for Patients with locally Advanced Squamous Cell Cancer of the Head and Neck. J Clin Oncol 24:4163-9, 2006.
16. Papadimitrakopoulou V, Adjei AA. The Akt/mTOR and MAP Kinase Pathways in Lung Cancer Therapy. J Thor Oncol 1 (7):749-51, 2006.

Last updated: 1/10/2013